Nucleoside Analogue Can Improve the Long-Term Prognosis of Patients with Hepatitis B Virus Infection-Associated Acute on Chronic Liver Failure
- 29 May 2010
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 55 (8) , 2373-2380
Abstract
The prognosis of patients with hepatitis B virus (HBV)-associated acute on chronic liver failure (ACLF) is extremely poor. This study was designed to evaluate the efficacy and safety of nucleoside analogue treatment of patients with HBV-associated ACLF. We used a retrospective review of eligible patients from April 2006 to December 2008. Eligible subjects received 0.5 mg entecavir daily until October 2009 (group A), 100 mg lamivudine daily until October 2009 (group B), or no nucleoside analogue (group C). The primary endpoints were three-month survival and the rate of recurrence of HBV-associated ACLF. The secondary endpoints were HBV DNA levels, liver function, the model of end-stage liver disease (MELD) score, and adverse events. A total of 104 consecutive patients were recruited, and 33, 34, and 37 patients were randomly allocated to groups A, B, and C, respectively. Although no significant difference in three-month survival was observed, levels of HBV DNA and rates of recurrence of HBV-associated ACLF were lower. Liver function and MELD score were not significantly improved despite significantly reduced HBV DNA levels. These data indicated that nucleoside analogue treatment did not improve the short-term prognosis of patients with HBV-associated ACLF although it was efficacious and safe in the management of HBV DNA levels. Intriguingly and importantly, continuous nucleoside analogue treatment can significantly reduce the rate of recurrence, which might be indicative of the further benefit of long-term survival.Keywords
This publication has 34 references indexed in Scilit:
- Role of Cytokines in the Pathophysiology of Acute-on-Chronic Liver FailureBlood Purification, 2009
- Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)Hepatology International, 2008
- Prediction value of model for end‐stage liver disease scoring system on prognosis in patients with acute‐on‐chronic hepatitis B liver failure after plasma exchange and lamivudine treatmentJournal of Gastroenterology and Hepatology, 2008
- Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis BJournal of Gastroenterology and Hepatology, 2005
- Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to LamivudineAntimicrobial Agents and Chemotherapy, 2004
- Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis BHepatology, 2002
- Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantationJournal of Medical Virology, 2002
- Spontaneous Reactivation in Chronic Hepatitis BJournal of Clinical Gastroenterology, 1990
- Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis BHepatology, 1990
- Transplantation of the liver in adults and children with fulminant hepatic failureJournal of Hepatology, 1988